ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2018
A Subset of Mesotheliomas With Improved Survival Occurring in Carriers of BAP1 and Other Germline Mutations.
Open access · greenAbstract read
In one paragraph
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers.
0numbers the graph read from it
0cells of the map it votes in
81citing papers in PubMed
12.3field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
81 citing papers in PubMed, 138 citations in OpenAlex.
- Brief report: attitudes and barriers toward genetic testing in pleural mesothelioma: a nationwide Italian survey.Familial cancer · 2026Article
- Epidemiological and Prognostic Differences in Malignant Mesothelioma Between Eastern China and SEER Database.Cancer science · 2026Article
- Distinct epidemiologic patterns of mesothelioma: evidence from a 16-year provincial cohort in China.BMC cancer · 2026Article
- Diagnosis and management of pleural mesothelioma: three unique cases and review of the literature.BMC pulmonary medicine · 2026Review
- The genetics of cancer heterogeneity and mesothelioma.Frontiers in oncology · 2026Review
- Advances in the Basic Sciences in Thoracic Oncology in the Last 20 Years and Their Translational Impact.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2026Review
- Tumor suppressor BAP1 emerges as a key regulator of metabolism and cell death in tumors.Frontiers in cell and developmental biology · 2026Review
- Review
- Review
- Prospective Analysis of Mesotheliomas in Subjects With BAP1 Cancer Syndrome: Clinical Characteristics and Epigenetic Correlates of Disease.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2025Observational
- Clinical and Pathologic Phenotyping of Mesotheliomas Developing in Carriers of Germline BAP1 Mutations.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2025Article
- Trends in Mesothelioma Mortality in the United States Between 1999 and 2020.JTO clinical and research reports · 2025Article
- Correlation of Histologic Features with Gene Alterations in Pleural Mesothelioma.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2025Article
- An overview of BAP1 biological functions and current therapeutics.Biochimica et biophysica acta. Reviews on cancer · 2025Review
- Loss of histone deubiquitinase Bap1 triggers anti-tumor immunity.Cellular oncology (Dordrecht, Netherlands) · 2025Article
- Bayesian analysis of the rate of spontaneous malignant mesothelioma among BAP1 mutant mice in the absence of asbestos exposure.Scientific reports · 2025Article
- Therapeutic Strategies to Improve the Treatment of Pleural Mesothelioma.Current medicinal chemistry · 2025Review
- Expanded detection and impact ofNAR cancer · 2024Article
- Review
- Diagnosis of Pleural Mesothelioma: Is Everything Solved at the Present Time?Current oncology (Toronto, Ont.) · 2024Review
21 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 3 institutions in 2 countries.
Sandra PastorinoSandra Pastorino, Mitsuru Emi, Masaki Nasu, Ian Pagano, Yasutaka Takinishi, Ryuji Yamamoto, Michael Minaai, Keisuke Goto, Mika Tanji, Angela Bononi, Andrea Napolitano, Giovanni Gaudino, Haining Yang, and Michele Carbone, University of Hawaii Cancer Center, Honolulu, HI; Yoshie Yoshikawa, Mitsuru Emi, Tomoko Hashimoto-Tamaoki, and Masaki Ohmuraya, Hyogo College of Medicine, Hyogo, Japan; Mary Hesdorffer, Mesothelioma Applied Research Foundation, Washington DC; Harvey I. Pass and Chandra Goparaju, New York University Langone Medical Center, New York, NY; Andrea Neopolitano, University Campus Bio-Medico, Rome, Italy; and Kavita Y. Sarin, Stanford University, Stanford, CA.
Yoshie YoshikawaSandra Pastorino, Mitsuru Emi, Masaki Nasu, Ian Pagano, Yasutaka Takinishi, Ryuji Yamamoto, Michael Minaai, Keisuke Goto, Mika Tanji, Angela Bononi, Andrea Napolitano, Giovanni Gaudino, Haining Yang, and Michele Carbone, University of Hawaii Cancer Center, Honolulu, HI; Yoshie Yoshikawa, Mitsuru Emi, Tomoko Hashimoto-Tamaoki, and Masaki Ohmuraya, Hyogo College of Medicine, Hyogo, Japan; Mary Hesdorffer, Mesothelioma Applied Research Foundation, Washington DC; Harvey I. Pass and Chandra Goparaju, New York University Langone Medical Center, New York, NY; Andrea Neopolitano, University Campus Bio-Medico, Rome, Italy; and Kavita Y. Sarin, Stanford University, Stanford, CA.
Harvey I PassSandra Pastorino, Mitsuru Emi, Masaki Nasu, Ian Pagano, Yasutaka Takinishi, Ryuji Yamamoto, Michael Minaai, Keisuke Goto, Mika Tanji, Angela Bononi, Andrea Napolitano, Giovanni Gaudino, Haining Yang, and Michele Carbone, University of Hawaii Cancer Center, Honolulu, HI; Yoshie Yoshikawa, Mitsuru Emi, Tomoko Hashimoto-Tamaoki, and Masaki Ohmuraya, Hyogo College of Medicine, Hyogo, Japan; Mary Hesdorffer, Mesothelioma Applied Research Foundation, Washington DC; Harvey I. Pass and Chandra Goparaju, New York University Langone Medical Center, New York, NY; Andrea Neopolitano, University Campus Bio-Medico, Rome, Italy; and Kavita Y. Sarin, Stanford University, Stanford, CA.
Mitsuru EmiSandra Pastorino, Mitsuru Emi, Masaki Nasu, Ian Pagano, Yasutaka Takinishi, Ryuji Yamamoto, Michael Minaai, Keisuke Goto, Mika Tanji, Angela Bononi, Andrea Napolitano, Giovanni Gaudino, Haining Yang, and Michele Carbone, University of Hawaii Cancer Center, Honolulu, HI; Yoshie Yoshikawa, Mitsuru Emi, Tomoko Hashimoto-Tamaoki, and Masaki Ohmuraya, Hyogo College of Medicine, Hyogo, Japan; Mary Hesdorffer, Mesothelioma Applied Research Foundation, Washington DC; Harvey I. Pass and Chandra Goparaju, New York University Langone Medical Center, New York, NY; Andrea Neopolitano, University Campus Bio-Medico, Rome, Italy; and Kavita Y. Sarin, Stanford University, Stanford, CA.
Masaki NasuSandra Pastorino, Mitsuru Emi, Masaki Nasu, Ian Pagano, Yasutaka Takinishi, Ryuji Yamamoto, Michael Minaai, Keisuke Goto, Mika Tanji, Angela Bononi, Andrea Napolitano, Giovanni Gaudino, Haining Yang, and Michele Carbone, University of Hawaii Cancer Center, Honolulu, HI; Yoshie Yoshikawa, Mitsuru Emi, Tomoko Hashimoto-Tamaoki, and Masaki Ohmuraya, Hyogo College of Medicine, Hyogo, Japan; Mary Hesdorffer, Mesothelioma Applied Research Foundation, Washington DC; Harvey I. Pass and Chandra Goparaju, New York University Langone Medical Center, New York, NY; Andrea Neopolitano, University Campus Bio-Medico, Rome, Italy; and Kavita Y. Sarin, Stanford University, Stanford, CA.
Ian PaganoSandra Pastorino, Mitsuru Emi, Masaki Nasu, Ian Pagano, Yasutaka Takinishi, Ryuji Yamamoto, Michael Minaai, Keisuke Goto, Mika Tanji, Angela Bononi, Andrea Napolitano, Giovanni Gaudino, Haining Yang, and Michele Carbone, University of Hawaii Cancer Center, Honolulu, HI; Yoshie Yoshikawa, Mitsuru Emi, Tomoko Hashimoto-Tamaoki, and Masaki Ohmuraya, Hyogo College of Medicine, Hyogo, Japan; Mary Hesdorffer, Mesothelioma Applied Research Foundation, Washington DC; Harvey I. Pass and Chandra Goparaju, New York University Langone Medical Center, New York, NY; Andrea Neopolitano, University Campus Bio-Medico, Rome, Italy; and Kavita Y. Sarin, Stanford University, Stanford, CA.
Yasutaka TakinishiSandra Pastorino, Mitsuru Emi, Masaki Nasu, Ian Pagano, Yasutaka Takinishi, Ryuji Yamamoto, Michael Minaai, Keisuke Goto, Mika Tanji, Angela Bononi, Andrea Napolitano, Giovanni Gaudino, Haining Yang, and Michele Carbone, University of Hawaii Cancer Center, Honolulu, HI; Yoshie Yoshikawa, Mitsuru Emi, Tomoko Hashimoto-Tamaoki, and Masaki Ohmuraya, Hyogo College of Medicine, Hyogo, Japan; Mary Hesdorffer, Mesothelioma Applied Research Foundation, Washington DC; Harvey I. Pass and Chandra Goparaju, New York University Langone Medical Center, New York, NY; Andrea Neopolitano, University Campus Bio-Medico, Rome, Italy; and Kavita Y. Sarin, Stanford University, Stanford, CA.
Ryuji YamamotoSandra Pastorino, Mitsuru Emi, Masaki Nasu, Ian Pagano, Yasutaka Takinishi, Ryuji Yamamoto, Michael Minaai, Keisuke Goto, Mika Tanji, Angela Bononi, Andrea Napolitano, Giovanni Gaudino, Haining Yang, and Michele Carbone, University of Hawaii Cancer Center, Honolulu, HI; Yoshie Yoshikawa, Mitsuru Emi, Tomoko Hashimoto-Tamaoki, and Masaki Ohmuraya, Hyogo College of Medicine, Hyogo, Japan; Mary Hesdorffer, Mesothelioma Applied Research Foundation, Washington DC; Harvey I. Pass and Chandra Goparaju, New York University Langone Medical Center, New York, NY; Andrea Neopolitano, University Campus Bio-Medico, Rome, Italy; and Kavita Y. Sarin, Stanford University, Stanford, CA.
Michael MinaaiSandra Pastorino, Mitsuru Emi, Masaki Nasu, Ian Pagano, Yasutaka Takinishi, Ryuji Yamamoto, Michael Minaai, Keisuke Goto, Mika Tanji, Angela Bononi, Andrea Napolitano, Giovanni Gaudino, Haining Yang, and Michele Carbone, University of Hawaii Cancer Center, Honolulu, HI; Yoshie Yoshikawa, Mitsuru Emi, Tomoko Hashimoto-Tamaoki, and Masaki Ohmuraya, Hyogo College of Medicine, Hyogo, Japan; Mary Hesdorffer, Mesothelioma Applied Research Foundation, Washington DC; Harvey I. Pass and Chandra Goparaju, New York University Langone Medical Center, New York, NY; Andrea Neopolitano, University Campus Bio-Medico, Rome, Italy; and Kavita Y. Sarin, Stanford University, Stanford, CA.
Tomoko Hashimoto-TamaokiSandra Pastorino, Mitsuru Emi, Masaki Nasu, Ian Pagano, Yasutaka Takinishi, Ryuji Yamamoto, Michael Minaai, Keisuke Goto, Mika Tanji, Angela Bononi, Andrea Napolitano, Giovanni Gaudino, Haining Yang, and Michele Carbone, University of Hawaii Cancer Center, Honolulu, HI; Yoshie Yoshikawa, Mitsuru Emi, Tomoko Hashimoto-Tamaoki, and Masaki Ohmuraya, Hyogo College of Medicine, Hyogo, Japan; Mary Hesdorffer, Mesothelioma Applied Research Foundation, Washington DC; Harvey I. Pass and Chandra Goparaju, New York University Langone Medical Center, New York, NY; Andrea Neopolitano, University Campus Bio-Medico, Rome, Italy; and Kavita Y. Sarin, Stanford University, Stanford, CA.
Masaki OhmurayaSandra Pastorino, Mitsuru Emi, Masaki Nasu, Ian Pagano, Yasutaka Takinishi, Ryuji Yamamoto, Michael Minaai, Keisuke Goto, Mika Tanji, Angela Bononi, Andrea Napolitano, Giovanni Gaudino, Haining Yang, and Michele Carbone, University of Hawaii Cancer Center, Honolulu, HI; Yoshie Yoshikawa, Mitsuru Emi, Tomoko Hashimoto-Tamaoki, and Masaki Ohmuraya, Hyogo College of Medicine, Hyogo, Japan; Mary Hesdorffer, Mesothelioma Applied Research Foundation, Washington DC; Harvey I. Pass and Chandra Goparaju, New York University Langone Medical Center, New York, NY; Andrea Neopolitano, University Campus Bio-Medico, Rome, Italy; and Kavita Y. Sarin, Stanford University, Stanford, CA.
Keisuke GotoSandra Pastorino, Mitsuru Emi, Masaki Nasu, Ian Pagano, Yasutaka Takinishi, Ryuji Yamamoto, Michael Minaai, Keisuke Goto, Mika Tanji, Angela Bononi, Andrea Napolitano, Giovanni Gaudino, Haining Yang, and Michele Carbone, University of Hawaii Cancer Center, Honolulu, HI; Yoshie Yoshikawa, Mitsuru Emi, Tomoko Hashimoto-Tamaoki, and Masaki Ohmuraya, Hyogo College of Medicine, Hyogo, Japan; Mary Hesdorffer, Mesothelioma Applied Research Foundation, Washington DC; Harvey I. Pass and Chandra Goparaju, New York University Langone Medical Center, New York, NY; Andrea Neopolitano, University Campus Bio-Medico, Rome, Italy; and Kavita Y. Sarin, Stanford University, Stanford, CA.
Chandra GoparajuSandra Pastorino, Mitsuru Emi, Masaki Nasu, Ian Pagano, Yasutaka Takinishi, Ryuji Yamamoto, Michael Minaai, Keisuke Goto, Mika Tanji, Angela Bononi, Andrea Napolitano, Giovanni Gaudino, Haining Yang, and Michele Carbone, University of Hawaii Cancer Center, Honolulu, HI; Yoshie Yoshikawa, Mitsuru Emi, Tomoko Hashimoto-Tamaoki, and Masaki Ohmuraya, Hyogo College of Medicine, Hyogo, Japan; Mary Hesdorffer, Mesothelioma Applied Research Foundation, Washington DC; Harvey I. Pass and Chandra Goparaju, New York University Langone Medical Center, New York, NY; Andrea Neopolitano, University Campus Bio-Medico, Rome, Italy; and Kavita Y. Sarin, Stanford University, Stanford, CA.
Kavita Y SarinSandra Pastorino, Mitsuru Emi, Masaki Nasu, Ian Pagano, Yasutaka Takinishi, Ryuji Yamamoto, Michael Minaai, Keisuke Goto, Mika Tanji, Angela Bononi, Andrea Napolitano, Giovanni Gaudino, Haining Yang, and Michele Carbone, University of Hawaii Cancer Center, Honolulu, HI; Yoshie Yoshikawa, Mitsuru Emi, Tomoko Hashimoto-Tamaoki, and Masaki Ohmuraya, Hyogo College of Medicine, Hyogo, Japan; Mary Hesdorffer, Mesothelioma Applied Research Foundation, Washington DC; Harvey I. Pass and Chandra Goparaju, New York University Langone Medical Center, New York, NY; Andrea Neopolitano, University Campus Bio-Medico, Rome, Italy; and Kavita Y. Sarin, Stanford University, Stanford, CA.
Mika TanjiSandra Pastorino, Mitsuru Emi, Masaki Nasu, Ian Pagano, Yasutaka Takinishi, Ryuji Yamamoto, Michael Minaai, Keisuke Goto, Mika Tanji, Angela Bononi, Andrea Napolitano, Giovanni Gaudino, Haining Yang, and Michele Carbone, University of Hawaii Cancer Center, Honolulu, HI; Yoshie Yoshikawa, Mitsuru Emi, Tomoko Hashimoto-Tamaoki, and Masaki Ohmuraya, Hyogo College of Medicine, Hyogo, Japan; Mary Hesdorffer, Mesothelioma Applied Research Foundation, Washington DC; Harvey I. Pass and Chandra Goparaju, New York University Langone Medical Center, New York, NY; Andrea Neopolitano, University Campus Bio-Medico, Rome, Italy; and Kavita Y. Sarin, Stanford University, Stanford, CA.
Angela BononiSandra Pastorino, Mitsuru Emi, Masaki Nasu, Ian Pagano, Yasutaka Takinishi, Ryuji Yamamoto, Michael Minaai, Keisuke Goto, Mika Tanji, Angela Bononi, Andrea Napolitano, Giovanni Gaudino, Haining Yang, and Michele Carbone, University of Hawaii Cancer Center, Honolulu, HI; Yoshie Yoshikawa, Mitsuru Emi, Tomoko Hashimoto-Tamaoki, and Masaki Ohmuraya, Hyogo College of Medicine, Hyogo, Japan; Mary Hesdorffer, Mesothelioma Applied Research Foundation, Washington DC; Harvey I. Pass and Chandra Goparaju, New York University Langone Medical Center, New York, NY; Andrea Neopolitano, University Campus Bio-Medico, Rome, Italy; and Kavita Y. Sarin, Stanford University, Stanford, CA.
Andrea NapolitanoSandra Pastorino, Mitsuru Emi, Masaki Nasu, Ian Pagano, Yasutaka Takinishi, Ryuji Yamamoto, Michael Minaai, Keisuke Goto, Mika Tanji, Angela Bononi, Andrea Napolitano, Giovanni Gaudino, Haining Yang, and Michele Carbone, University of Hawaii Cancer Center, Honolulu, HI; Yoshie Yoshikawa, Mitsuru Emi, Tomoko Hashimoto-Tamaoki, and Masaki Ohmuraya, Hyogo College of Medicine, Hyogo, Japan; Mary Hesdorffer, Mesothelioma Applied Research Foundation, Washington DC; Harvey I. Pass and Chandra Goparaju, New York University Langone Medical Center, New York, NY; Andrea Neopolitano, University Campus Bio-Medico, Rome, Italy; and Kavita Y. Sarin, Stanford University, Stanford, CA.
Giovanni GaudinoSandra Pastorino, Mitsuru Emi, Masaki Nasu, Ian Pagano, Yasutaka Takinishi, Ryuji Yamamoto, Michael Minaai, Keisuke Goto, Mika Tanji, Angela Bononi, Andrea Napolitano, Giovanni Gaudino, Haining Yang, and Michele Carbone, University of Hawaii Cancer Center, Honolulu, HI; Yoshie Yoshikawa, Mitsuru Emi, Tomoko Hashimoto-Tamaoki, and Masaki Ohmuraya, Hyogo College of Medicine, Hyogo, Japan; Mary Hesdorffer, Mesothelioma Applied Research Foundation, Washington DC; Harvey I. Pass and Chandra Goparaju, New York University Langone Medical Center, New York, NY; Andrea Neopolitano, University Campus Bio-Medico, Rome, Italy; and Kavita Y. Sarin, Stanford University, Stanford, CA.
Mary HesdorfferSandra Pastorino, Mitsuru Emi, Masaki Nasu, Ian Pagano, Yasutaka Takinishi, Ryuji Yamamoto, Michael Minaai, Keisuke Goto, Mika Tanji, Angela Bononi, Andrea Napolitano, Giovanni Gaudino, Haining Yang, and Michele Carbone, University of Hawaii Cancer Center, Honolulu, HI; Yoshie Yoshikawa, Mitsuru Emi, Tomoko Hashimoto-Tamaoki, and Masaki Ohmuraya, Hyogo College of Medicine, Hyogo, Japan; Mary Hesdorffer, Mesothelioma Applied Research Foundation, Washington DC; Harvey I. Pass and Chandra Goparaju, New York University Langone Medical Center, New York, NY; Andrea Neopolitano, University Campus Bio-Medico, Rome, Italy; and Kavita Y. Sarin, Stanford University, Stanford, CA.
Haining YangSandra Pastorino, Mitsuru Emi, Masaki Nasu, Ian Pagano, Yasutaka Takinishi, Ryuji Yamamoto, Michael Minaai, Keisuke Goto, Mika Tanji, Angela Bononi, Andrea Napolitano, Giovanni Gaudino, Haining Yang, and Michele Carbone, University of Hawaii Cancer Center, Honolulu, HI; Yoshie Yoshikawa, Mitsuru Emi, Tomoko Hashimoto-Tamaoki, and Masaki Ohmuraya, Hyogo College of Medicine, Hyogo, Japan; Mary Hesdorffer, Mesothelioma Applied Research Foundation, Washington DC; Harvey I. Pass and Chandra Goparaju, New York University Langone Medical Center, New York, NY; Andrea Neopolitano, University Campus Bio-Medico, Rome, Italy; and Kavita Y. Sarin, Stanford University, Stanford, CA.
Michele CarboneSandra Pastorino, Mitsuru Emi, Masaki Nasu, Ian Pagano, Yasutaka Takinishi, Ryuji Yamamoto, Michael Minaai, Keisuke Goto, Mika Tanji, Angela Bononi, Andrea Napolitano, Giovanni Gaudino, Haining Yang, and Michele Carbone, University of Hawaii Cancer Center, Honolulu, HI; Yoshie Yoshikawa, Mitsuru Emi, Tomoko Hashimoto-Tamaoki, and Masaki Ohmuraya, Hyogo College of Medicine, Hyogo, Japan; Mary Hesdorffer, Mesothelioma Applied Research Foundation, Washington DC; Harvey I. Pass and Chandra Goparaju, New York University Langone Medical Center, New York, NY; Andrea Neopolitano, University Campus Bio-Medico, Rome, Italy; and Kavita Y. Sarin, Stanford University, Stanford, CA.
Eisai (United Kingdom) · GBHyogo Medical University · JPTakeda (Japan) · JP
Funding
The North American Mesothelioma ConsortiumU01CA111295 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI HUFLEJT, MARGARET ELISABETH, PASS, HARVEY IRA · 2005 to 2016
$4.8MGermline BAP1 Mutations and Malignant Mesothelioma: Mechanisms and Early DetectionR01CA198138 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI CARBONE, MICHELE · 2015 to 2019
$1.7MNCI NIH HHS R01 CA198138NCI NIH HHS U01 CA111295
Abstract
purposeWe hypothesized that four criteria could help identify malignant mesotheliomas (MMs) most likely linked to germline mutations of BAP1 or of other genes: family history of MM, BAP1-associated cancers, or multiple malignancies; or age younger than 50 years. PATIENTS AND
methodsOver the course of 7 years, 79 patients with MM met the four criteria; 22 of the 79 (28%) reported possible asbestos exposure. They were screened for germline BAP1 mutations by Sanger sequencing and by targeted next-generation sequencing (tNGS) for germline mutations in 55 additional cancer-linked genes. Deleterious mutations detected by tNGS were validated by Sanger sequencing.
resultsOf the 79 patients, 43 (16 probands and 27 relatives) had deleterious germline BAP1 mutations. The median age at diagnosis was 54 years and median survival was 5 years. Among the remaining 36 patients with no BAP1 mutation, median age at diagnosis was 45 years, median survival was 9 years, and 12 had deleterious mutations of additional genes linked to cancer. When compared with patients with MMs in the SEER cohort, median age at diagnosis (72 years), median survival for all MM stages (8 months), and stage I (11 months) were significantly different from the 79 patients with MM in the current study ( P < .0001).
conclusionWe provide criteria that help identify a subset of patients with MM who had significantly improved survival. Most of these patients were not aware of asbestos exposure and carried either pathogenic germline mutations of BAP1 or of additional genes linked to cancer, some of which may have targeted-therapy options. These patients and their relatives are susceptible to development of additional cancers; therefore, genetic counseling and cancer screening should be considered.
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.